Healthy Skepticism Library item: 2454
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Hoogenberg K, van der Tuin J.
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
Ned Tijdschr Geneeskd. 2002 November 2; 146:(44):2099-100
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12448967
Abstract:
A number of Dutch medical journals have carried an advertisement promoting doxazosin in the treatment of hypertension in patients with type 2 diabetes mellitus. No long-term randomised clinical trials have examined the cardiovascular outcomes of the alpha-adrenergic blockers to which doxazosin belongs. The drug was removed from the largest study into blood pressure and cholesterol reduction ever performed until now (the antihypertensive and lipid-lowering treatment to prevent heart attack trial), due to an increased incidence of cardiovascular events and in particular congestive heart failure. The clinical significance of its insulin-sensitivity improving and lipid-neutralising effects in small-scale, short-term, small patient-group studies are ambiguous. Accordingly, national and international guidelines omitted the drug in their treatment recommendations. The advertisement claims are therefore misleading
Keywords:
*analysis
Netherlands
journal advertisements
doxazosin
hypertension
diabetes
EVALUATION OF PROMOTION: JOURNAL ADVERTISEMENTS
PROMOTIONAL TECHNIQUES: JOURNAL ADVERTISEMENTS
Adrenergic alpha-Antagonists/adverse effects*
Adrenergic alpha-Antagonists/therapeutic use
Advertising/standards*
Antihypertensive Agents/adverse effects*
Antihypertensive Agents/therapeutic use
Cardiovascular Diseases/chemically induced
Diabetes Mellitus, Type 2/complications*
Doxazosin/adverse effects*
Doxazosin/therapeutic use
English Abstract
Humans
Hypertension/drug therapy*
Hypertension/etiology
Netherlands
Practice Guidelines
Treatment Outcome
